Bayer reported Q1 2026 core EPS of €2.71, surpassing expectations and lifting shares over 6% in the market.
EBITDA before special items rose 9% to €4.45bn, while net income reached €2.76bn, beating forecasts of €1.58bn for the quarter.
Crop Science sales grew 6.8% to €7.56bn and EBITDA margin expanded to 39.9%, aided by €448m Corteva settlement in North America.
Free cash flow turned negative €2.32bn due to €2bn litigation payments; net financial debt increased to €32.52bn by end of Q1.